Pluri Inc. Asset Resilience Ratio

Latest as of March 2026: 22.65%

Pluri Inc. asset resilience ratio. Pluri Inc. (PLUR) has an Asset Resilience Ratio of 22.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PLUR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$5.90 Million
Cash + Short-term Investments

Total Assets

$26.06 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Pluri Inc. (2007–2025)

Asset resilience ratio of Pluri Inc. from 2007 to 2025. This chart shows how Pluri Inc.'s Asset Resilience Ratio has changed over time. Read PLUR current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Pluri Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pluri Inc. balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $5.90 Million 22.65%
Total Liquid Assets $5.90 Million 22.65%

Asset Resilience Insights

  • Good Liquidity Position: Pluri Inc. maintains a healthy 22.65% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Pluri Inc. Industry Peers by Asset Resilience Ratio

Compare Pluri Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

Pluri Inc. Asset Resilience Ratio by Year (2007–2025)

Pluri Inc. asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Pluri Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 38.05% $14.72 Million $38.68 Million -20.65pp
2024-06-30 58.70% $23.20 Million $39.53 Million -9.83pp
2023-06-30 68.53% $34.81 Million $50.80 Million +2.06pp
2022-06-30 66.47% $45.24 Million $68.06 Million +30.43pp
2021-06-30 36.04% $33.71 Million $93.54 Million -21.21pp
2020-06-30 57.25% $37.51 Million $65.53 Million -5.35pp
2019-06-30 62.60% $19.60 Million $31.31 Million +8.49pp
2018-06-30 54.10% $21.08 Million $38.96 Million -2.91pp
2017-06-30 57.01% $21.40 Million $37.53 Million +0.45pp
2016-06-30 56.56% $25.98 Million $45.94 Million +13.40pp
2015-06-30 43.16% $29.42 Million $68.16 Million -23.59pp
2014-06-30 66.75% $49.41 Million $74.02 Million +1.04pp
2013-06-30 65.71% $44.89 Million $68.32 Million +50.90pp
2012-06-30 14.81% $7.02 Million $47.42 Million -10.13pp
2009-06-30 24.94% $1.11 Million $4.46 Million -8.13pp
2008-06-30 33.06% $1.19 Million $3.58 Million -22.81pp
2007-06-30 55.87% $3.76 Million $6.73 Million --
pp = percentage points

About Pluri Inc.

NASDAQ:PLUR USA Biotechnology
Market Cap
$14.39 Million
Market Cap Rank
#25966 Global
#5463 in USA
Share Price
$1.20
Change (1 day)
-3.23%
52-Week Range
$0.85 - $4.45
All Time High
$160.00
About

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, … Read more